Allergan, Inc.

Allergan Sales, Inc.

Dose Medical Corporation

Glaukos Corporation

Patrick Michael Hughes

Michael R Robinson

James A Burke

Orest Olejnik

Wendy M Blanda

Thomas C Malone

James Nienyuan Chang

Lon T Spada

Scott M Whitcup

Joan-En Chang-Lin

Jeffrey L Edelman

Gerald Woodrow DeVries

Larry Allen Wheeler

Glenn T Huang

Christian Sarrazin

Thierry Nivaggioli

John S Kent

Rosy Sheng Donn

Jane-Guo Shiah

Marina Do

David Frederick Woodward

Julie Wurster

Chin-Ming Chang

Jinping Wan

Robert M Burk

Danny Thang Dinh

Ahmet Tezel

Terrence J Hunt

Ke Wu

Gyorgy F Ambrus

Alazar N Ghebremeskel

Lance Steward

Ester Fernandez-Salas

Joseph Francis

Futian Liu

Xiaojie Yu

Robert T Lyons

John T Trogden

Xialing Guo

Sougato Boral

Guadalupe Ruiz

Hui Liu

Ton Lin

Michele Boix

Jane Guo Shiah

Kai-Ming Zhang

Brittany A Jackson

Gerald W De Vries

Jie Shen

Elisabeth Rossi

Chandrasekar Durairaj

Roger Kei Aoki

Devin F Welty

Werhner C Orilla

Ina Mustafaj

Jeffery L Edelman

Joan-En Lin

Kelly M Harrison

David C Rupp

Peter C Baciu

Eric A Forssen

Guang Wei Lu

Tom V Burns

Ron S Broide

Maria Escobar

Jia-Ying Yang

James Shiah

Jack Xie

Sheshadri Neervannan

Cindy W Wu

Gary Shimizu

Rosy Sheng

Orilla C Werhner

Michèle Boix

Kun Xu

Gerald W Devries

Marianne M Do

A James Burke

Ruwen Shi

The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.

Bioerodible cross-linked hydrogel implants and related methods of use

The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

Rho kinase inhibitor releasing implants and related methods of use

The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.

Bioerodible polyester polymer axitinib ocular implants and related methods of use

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25&#xb0; C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25&#xb0; C. is in the range of from about 80,000 cps to about 300,000 cps.

High viscosity macromolecular compositions for treating ocular conditions

Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.

Microneedle array with active ingredient

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Biodegradable intravitreal tyrosine kinase implants

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Hypotensive lipid-containing biodegradable intraocular implants and related methods

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

Dermal filler

The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.

Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Prostamide-containing intraocular implant

Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.

Biodegradable drug delivery systems for the sustained release of proteins

Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.

Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Hypotensive lipid-containing biodegradable intraocular implants and related implants

Growing community of inventors

Aliso Viejo, CA, United States of America

Patrick Michael Hughes